Oncology Therapeutic Drug Monitoring Market: By Monoclonal Antibody Type, Adalimumab, Vedolizumab, Ustekinumab, Golimumab, Etanercept, Rituximab, Tocilizumab, By Technology Type and Region Forecast 2020-2031
Oncology Therapeutic Drug Monitoring Market size was valued at US$ 2.3 billion in 2024 and is expected to reach US$ 4.1 billion by 2031, growing at a significant CAGR of 8.4% from 2025-2031. The global market provides a detailed overview of the market and that can be segmented by monoclonal antibody type, and technology type. By monoclonal antibody type, the market has been segmented into infliximab (IFX), adalimumab (ADL), vedolizumab (VDL), ustekinumab (UTK), golimumab (GLM), Etanercept (ETN), rituximab (RTX), tocilizumab (TCZ)). The golimumab (GLM)segment is likely to be the largest and fastest-growing segment in terms of monoclonal antibody type. Based on technology type, the market is segmented into immunoassay and others. Among these, the immunoassay segment is expected to have the fastest-growing market during the forecast period 2025-2031.
In July 2021, Roche announced the approval of "Ronapreve" (casirivimab and indevimab) for intravenous infusion treatment of patients with mild to moderate COVID-19. Under Article 14-3 of the Pharmaceuticals and Medical Devices Act, the antibody combination received Special Approval.
Study Period
2025-2031Base Year
2024CAGR
8.4%Largest Market
North-AmericaFastest Growing Market
North-America
The market has been growing due to the rising demand for monoclonal antibodies (mABs) as a result of the COVID-19 pandemic. The Food and Drug Administration (FDA) issued an emergency use authorization (EUA) for three monoclonal antibodies intended for outpatient treatment of symptomatic COVID-19 patients in response to the high transmission and significant fatality rates.
North American market is expected to witness the highest market share during the forecast period due to the well-established healthcare infrastructure. Furthermore, over the projected period, increased government support for cancer research and technology development is expected to stimulate the development of therapeutic proteins. Other major factors assisting the expansion of the industry are government assistance for infection control and management, the rising incidence of lifestyle-related disorders, and the growing population.
Latin America
Europe
Asia Pacific
Middle East
North America
|
Report Benchmarks |
Details |
|
Report Study Period |
2025-2031 |
|
Market Size in 2024 |
US$ 2.3 billion |
|
Market Size in 2031 |
US$ 4.1 billion |
|
Market CAGR |
8.4% |
|
By Monoclonal Antibody |
|
|
By Technology |
|
|
By Region |
|
Download Free Sample Report
Oncology Therapeutic Drug Monitoring Market size was valued at US$ 2.3 billion in 2024 and is expected to reach US$ 4.1 billion by 2031, growing at a significant CAGR of 8.4% from 2025-2031.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
The market key players are Grifols, S.A., Miraca Life Sciences, Prometheus Laboratories Inc., R-biopharm
| 1. Executive Summary |
| 2. Global Oncology Therapeutic Drug Monitoring Market Introduction |
| 2.1. Global Oncology Therapeutic Drug Monitoring Market Taxonomy |
| 2.2. Global Oncology Therapeutic Drug Monitoring Market Definitions |
| 2.2.1. Monoclonal Antibody Type |
| 2.2.2. Technology Type |
| 2.2.3. Region |
| 3. Global Oncology Therapeutic Drug Monitoring Market Dynamics |
| 3.1. Drivers |
| 3.2. Restraints |
| 3.3. Opportunities/Unmet Needs of the Market |
| 3.4. Trends |
| 3.5. Global Oncology Therapeutic Drug Monitoring Market Dynamic Factors - Impact Analysis |
| 3.6. New Monoclonal Antibody Monitoring Test Launches |
| 3.7. Mergers and Acquisitions |
| 4. Global Oncology Therapeutic Drug Monitoring Market Analysis, 2020- 2024 and Forecast, 2025-2031 |
| 4.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) |
| 4.3. Market Opportunity Analysis |
| 5. Global Oncology Therapeutic Drug Monitoring Market, By Monoclonal Antibody Type, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.1. Infliximab (IFX) |
| 5.1.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.1.3. Market Opportunity Analysis |
| 5.2. Adalimumab (ADL) |
| 5.2.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.2.3. Market Opportunity Analysis |
| 5.3. Vedolizumab (VDL) |
| 5.3.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.3.3. Market Opportunity Analysis |
| 5.4. Ustekinumab (UTK) |
| 5.4.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.4.3. Market Opportunity Analysis |
| 5.5. Golimumab (GLM) |
| 5.5.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.5.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.5.3. Market Opportunity Analysis |
| 5.6. Etanercept (ETN) |
| 5.6.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.6.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.6.3. Market Opportunity Analysis |
| 5.7. Rituximab (RTX) |
| 5.7.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.7.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.7.3. Market Opportunity Analysis |
| 5.8. Tocilizumab (TCZ) |
| 5.8.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 5.8.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 5.8.3. Market Opportunity Analysis |
| 6. Global Oncology Therapeutic Drug Monitoring Market Forecast, By Technology, 2020- 2024 and Forecast, 2025-2031 |
| 6.1. Immunoassay |
| 6.1.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 6.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.1.3. Market Opportunity Analysis |
| 6.2. Others |
| 6.2.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 6.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 6.2.3. Market Opportunity Analysis |
| 7. Global Oncology Therapeutic Drug Monitoring Market Forecast, By Region, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 7.1. North America |
| 7.1.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 7.1.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.1.3. Market Opportunity Analysis |
| 7.2. EMEA (Europe, Middle East and Africa) |
| 7.2.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 7.2.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.2.3. Market Opportunity Analysis |
| 7.3. Asia-Pacific |
| 7.3.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 7.3.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.3.3. Market Opportunity Analysis |
| 7.4. Latin America |
| 7.4.1. Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 7.4.2. Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%) |
| 7.4.3. Market Opportunity Analysis |
| 7.5. Global Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology Type, and Region, 2023 - 2029 |
| 8. North America Oncology Therapeutic Drug Monitoring Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 8.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.1.1. Infliximab (IFX) |
| 8.1.2. Adalimumab (ADL) |
| 8.1.3. Vedolizumab (VDL) |
| 8.1.4. Ustekinumab (UTK) |
| 8.1.5. Golimumab (GLM) |
| 8.1.6. Etanercept (ETN) |
| 8.1.7. Rituximab (RTX) |
| 8.1.8. Tocilizumab (TCZ) |
| 8.2. Technology Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 8.2.1. Immunoassay |
| 8.2.2. Others |
| 8.3. Country Analysis 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 8.3.1. U.S. |
| 8.3.2. Canada |
| 8.4. North America Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 8.5. North America Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 9. EMEA Oncology Therapeutic Drug Monitoring Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 9.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.1.1. Infliximab (IFX) |
| 9.1.2. Adalimumab (ADL) |
| 9.1.3. Vedolizumab (VDL) |
| 9.1.4. Ustekinumab (UTK) |
| 9.1.5. Golimumab (GLM) |
| 9.1.6. Etanercept (ETN) |
| 9.1.7. Rituximab (RTX) |
| 9.1.8. Tocilizumab (TCZ) |
| 9.2. Technology Analysis, 2017 - 2021 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 9.2.1. Immunoassay |
| 9.2.2. Others |
| 9.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 9.3.1. Germany |
| 9.3.2. UK |
| 9.3.3. Spain |
| 9.3.4. Italy |
| 9.3.5. France |
| 9.3.6. Saudi Arabia |
| 9.3.7. Rest of EMEA |
| 9.4. EMEA Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 9.5. EMEA Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 10. Asia-Pacific Oncology Therapeutic Drug Monitoring Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 10.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.1.1. Infliximab (IFX) |
| 10.1.2. Adalimumab (ADL) |
| 10.1.3. Vedolizumab (VDL) |
| 10.1.4. Ustekinumab (UTK) |
| 10.1.5. Golimumab (GLM) |
| 10.1.6. Etanercept (ETN) |
| 10.1.7. Rituximab (RTX) |
| 10.1.8. Tocilizumab (TCZ) |
| 10.2. Technology Analysis, 2017 - 2017 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 10.2.1. Immunoassay |
| 10.2.2. Others |
| 10.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 10.3.1. Japan |
| 10.3.2. China |
| 10.3.3. India |
| 10.3.4. Rest of Asia-Pacific |
| 10.4. Asia-Pacific Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 10.5. Asia-Pacific Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 11. Latin America Oncology Therapeutic Drug Monitoring Market Analysis, 2020- 2024 and Forecast, 2025-2031 (Revenue, USD Mn) |
| 11.1. Monoclonal Antibody Type Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.1.1. Infliximab (IFX) |
| 11.1.2. Adalimumab (ADL) |
| 11.1.3. Vedolizumab (VDL) |
| 11.1.4. Ustekinumab (UTK) |
| 11.1.5. Golimumab (GLM) |
| 11.1.6. Etanercept (ETN) |
| 11.1.7. Rituximab (RTX) |
| 11.1.8. Tocilizumab (TCZ) |
| 11.2. Technology Analysis, 2017 - 2017 and Forecast 2023 - 2029 by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%) |
| 11.2.1. Immunoassay |
| 11.2.2. Others |
| 11.3. Country Analysis 2018 - 2022 and Forecast 2023 - 2029 by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%) |
| 11.3.1. Brazil |
| 11.3.2. Mexico |
| 11.3.3. Rest of Latin America |
| 11.4. Latin America Oncology Therapeutic Drug Monitoring Market - Opportunity Analysis Index, By Monoclonal Antibody Type, Technology, and Country, 2023 - 2029 |
| 11.5. Latin America Oncology Therapeutic Drug Monitoring Market Dynamics Trends |
| 12. Competition Landscape |
| 12.1. Strategic Dashboard of Top Market Players |
| 12.2. Company Profiles (Introduction, Financial Analysis, Monoclonal Antibody Class & Service Offerings, Key Developments, Strategies, and SWOT Analysis) |
| 12.2.1. Grifols, S.A. |
| 12.2.2. Miraca Life Sciences |
| 12.2.3. Prometheus Laboratories Inc. |
| 12.2.4. R-biopharm |
| 12.2.5. BÃœHLMANN |
| 13. Research Methodology |
| 14. Key Assumptions and Acronyms |
Key Market Players
Author
Muni Kumar Meravath is a seasoned Healthcare Market Research Analyst with over 6 years of experience in the healthcare domain, encompassing pharmaceuticals, medical devices, and diagnostics. A graduate in Pharmacy, he possesses a strong foundation in the intricacies of the healthcare sector. He further enhanced his expertise by pursuing an MBA in Pharmaceuticals, equipping him with valuable business acumen. His analytical skills and market insights have contributed to strategic decision-making and enhanced market positioning for various healthcare organizations. Committed to driving innovation and excellence, Muni continues to seek opportunities to improve healthcare delivery through data-driven insights.
Download Sample
